{"id":880471,"date":"2025-08-29T08:39:23","date_gmt":"2025-08-29T12:39:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/"},"modified":"2025-08-29T08:39:23","modified_gmt":"2025-08-29T12:39:23","slug":"abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/","title":{"rendered":"Abbott&#8217;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>Navitor is now approved as a minimally invasive alternative to surgery for patients in <span class=\"xn-location\">Europe<\/span> with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk<\/li>\n<li>CE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in <i>JACC: Cardiovascular Interventions<\/i><\/li>\n<li>Updated guidelines announced for the management of valvular heart disease provide further support for mitral and tricuspid therapies like MitraClip\u2122 and TriClip\u2122 for leaky heart valves<\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-person\">ABBOTT PARK<\/span>, Ill.<\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 29, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Abbott (NYSE: ABT) today announced it has received CE Mark in <span class=\"xn-location\">Europe<\/span> for an expanded indication for the company&#8217;s Navitor\u2122 transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery. Abbott previously received CE Mark in 2021 for Navitor to treat people with symptomatic, severe aortic stenosis who are at high or extreme surgical risk. With this new approval, Navitor is available in <span class=\"xn-location\">Europe<\/span> for patients across all surgical risk categories, significantly expanding the number of people that can be treated with the device.<\/p>\n<p>The expanded indication was supported by favorable safety and effectiveness outcomes from the VANTAGE study, which was presented as a late breaker at the European Society of Cardiology (ESC) Congress 2025, held in <span class=\"xn-location\">Madrid<\/span> (<span class=\"xn-chron\">Aug. 29-Sept. 1, 2025<\/span>). These data were simultaneously\u00a0published\u00a0in <i><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4497209-1&amp;h=2855424649&amp;u=https%3A%2F%2Fwww.jacc.org%2Fdoi%2F10.1016%2Fj.jcin.2025.08.021&amp;a=JACC%3A+Cardiovascular+Interventions\" target=\"_blank\" rel=\"nofollow\">JACC: Cardiovascular Interventions<\/a><\/i><i>.<\/i>\u00a0<\/p>\n<p>&#8220;The VANTAGE study provides the scientific backbone for expanding Navitor&#8217;s indication to low- and intermediate-risk patients. The data are exceptional across both populations, confirming that the Navitor valve performs precisely as designed,&#8221; said <span class=\"xn-person\">Nicolas van Mieghem<\/span>, M.D., medical director of the department of interventional cardiology at the Thoraxcenter, <span class=\"xn-org\">Erasmus University<\/span> Medical Centre, in <span class=\"xn-location\">the Netherlands<\/span>, who serves as principal investigator of the VANTAGE trial. &#8220;Up to 50% of younger patients with aortic stenosis will also get coronary artery disease in later years, and Navitor&#8217;s design preserves options and ability for lifetime disease management if future cardiac interventions are required.&#8221;<\/p>\n<p>Aortic stenosis occurs when the aortic valve&#8217;s opening narrows, restricting blood flow to the body. Left untreated, it can lead to heart failure and death. The Navitor TAVI device replaces the aortic valve through a minimally invasive procedure and is delivered to the heart through a small incision in the leg. The performance of such devices is measured by blood flow through the valve, referred to as hemodynamics.<\/p>\n<p>\n        <b>Key findings from the VANTAGE trial<\/b><br \/>\n        <br \/>The late-breaking data presented at ESC from Abbott&#8217;s VANTAGE study showed Navitor met all safety and effectiveness primary endpoints, supporting its expansion to treat people with symptomatic,\u00a0severe aortic stenosis who are at low or intermediate surgical risk. Key findings include:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>Excellent safety.<\/b> In the first 262 patients with 12-month follow-up completed, there was a low rate (2.3%) of all-cause mortality or fatal stroke\/stroke with disability.<\/li>\n<li>\n          <b>Proven effectiveness.<\/b> No patients at 30 days had moderate or greater PVL (paravalvular leak or backflow of blood around the valve) and only 13.6% had mild PVL, a rate that is considered low.<sup>1,2,3,4<\/sup><\/li>\n<li>\n          <b>High technical success:<\/b> There was a high rate of technical success (97%) with no procedural deaths.<\/li>\n<li>\n          <b>Sustained hemodynamic performance.<\/b> Excellent hemodynamic performance was seen at 12 months.<\/li>\n<\/ul>\n<p>&#8220;Navitor is a strong example of how Abbott continues to evolve its structural heart portfolio to meet the growing demand for minimally invasive alternatives to open-heart surgery,&#8221; said\u00a0Sandra Lesenfants, senior vice president of Abbott&#8217;s structural heart business. &#8220;Aortic stenosis is a\u00a0life-threatening condition that can progress rapidly, and this expanded indication for Navitor means that patients have more options that can help reduce their symptoms and improve their lives.&#8221;<\/p>\n<p>The Navitor TAVI system is currently approved in the U.S. to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.<\/p>\n<p>\n        <b>Updated transcatheter edge-to-edge repair (TEER) guidelines<br \/><\/b>During ESC Congress 2025, ESC and the European Association for Cardio-Thoracic Surgery (EACTS) announced new guidelines for the management of valvular heart disease. Mitral valve TEER was upgraded from a treatment that <u>should be considered<\/u> (IIa) to a <u>recommended<\/u> treatment (Class Ia) for selected patients with severe functional (or secondary) mitral regurgitation (MR). Tricuspid valve TEER was also upgraded from a treatment that <u>may be considered<\/u> (IIb) to a treatment that <u>should be considered<\/u> (Class IIa) for selected patients with severe functional tricuspid regurgitation (TR).\u00a0<\/p>\n<p>With these updated guidelines, there&#8217;s additional support for the use of MitraClip\u2122 and TriClip\u2122 for MR and TR patients that is backed by evidence from multiple clinical studies, including COAPT, TRILUMINATE, TRILUMINATE Pivotal, bRIGHT, RESHAPE-HF2 and TRI.fr, that demonstrate the therapies&#8217; effectiveness.<\/p>\n<p>For U.S. important safety information about MitraClip and TriClip, visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4497209-1&amp;h=3951382679&amp;u=https%3A%2F%2Fabbo.tt%2FTEERG5ISI&amp;a=https%3A%2F%2Fabbo.tt%2FTEERG5ISI\" target=\"_blank\" rel=\"nofollow\">https:\/\/abbo.tt\/TEERG5ISI<\/a>.<\/p>\n<p>\n        <b>About Abbott:<br \/><\/b>Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.<\/p>\n<p>Connect with us at\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4497209-1&amp;h=2485482433&amp;u=http%3A%2F%2Fwww.abbott.com%2F&amp;a=www.abbott.com\" target=\"_blank\" rel=\"nofollow\">www.abbott.com<\/a> and on <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4497209-1&amp;h=1308563503&amp;u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fabbott-%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>, <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4497209-1&amp;h=2752477999&amp;u=https%3A%2F%2Fwww.facebook.com%2FAbbott%2F&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a>, <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4497209-1&amp;h=2457311803&amp;u=https%3A%2F%2Fwww.instagram.com%2Fabbottglobal%2F&amp;a=Instagram\" target=\"_blank\" rel=\"nofollow\">Instagram<\/a>, <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4497209-1&amp;h=3648652820&amp;u=https%3A%2F%2Ftwitter.com%2FAbbottNews&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a> and <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4497209-1&amp;h=222366762&amp;u=https%3A%2F%2Fwww.youtube.com%2Fc%2Fabbott&amp;a=YouTube\" target=\"_blank\" rel=\"nofollow\">YouTube<\/a>. \u00a0<\/p>\n<p>\n        <sup>1 <\/sup>Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 2016;387(10034):2218\u20132225; doi: 10.1016\/S0140-6736(16)30073-3.<br \/><sup>2<\/sup> Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O&#8217;Hair D, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med 2019;380(18):1706\u20131715; doi: 10.1056\/NEJMoa1816885.<br \/><sup>3<\/sup> Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019;380(18):1695\u20131705; doi: 10.1056\/NEJMoa1814052.<br \/><sup>4<\/sup>\u00a0Makkar RR, Ramana RK, Gnall E, et al. ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial. The Lancet. 2025;405:2061\u20132074.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG60758&amp;sd=2025-08-29\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis-302541887.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis-302541887.html<\/a><\/p>\n<p>SOURCE  Abbott<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG60758&amp;Transmission_Id=202508290800PR_NEWS_USPR_____CG60758&amp;DateId=20250829\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk CE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in JACC: Cardiovascular Interventions Updated guidelines announced for the management of valvular heart disease provide further support for mitral and tricuspid therapies like MitraClip\u2122 and TriClip\u2122 for leaky heart valves ABBOTT PARK, Ill., Aug. 29, 2025 \/PRNewswire\/ &#8212; Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for an expanded indication for the company&#8217;s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Abbott&#8217;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-880471","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abbott&#039;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbott&#039;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk CE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in JACC: Cardiovascular Interventions Updated guidelines announced for the management of valvular heart disease provide further support for mitral and tricuspid therapies like MitraClip\u2122 and TriClip\u2122 for leaky heart valves ABBOTT PARK, Ill., Aug. 29, 2025 \/PRNewswire\/ &#8212; Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for an expanded indication for the company&#8217;s &hellip; Continue reading &quot;Abbott&#8217;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T12:39:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG60758&amp;sd=2025-08-29\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abbott&#8217;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis\",\"datePublished\":\"2025-08-29T12:39:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/\"},\"wordCount\":1012,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG60758&amp;sd=2025-08-29\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/\",\"name\":\"Abbott's Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG60758&amp;sd=2025-08-29\",\"datePublished\":\"2025-08-29T12:39:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG60758&amp;sd=2025-08-29\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG60758&amp;sd=2025-08-29\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbott&#8217;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abbott's Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/","og_locale":"en_US","og_type":"article","og_title":"Abbott's Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis - Market Newsdesk","og_description":"PR Newswire Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk CE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in JACC: Cardiovascular Interventions Updated guidelines announced for the management of valvular heart disease provide further support for mitral and tricuspid therapies like MitraClip\u2122 and TriClip\u2122 for leaky heart valves ABBOTT PARK, Ill., Aug. 29, 2025 \/PRNewswire\/ &#8212; Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for an expanded indication for the company&#8217;s &hellip; Continue reading \"Abbott&#8217;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-29T12:39:23+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG60758&amp;sd=2025-08-29","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abbott&#8217;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis","datePublished":"2025-08-29T12:39:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/"},"wordCount":1012,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG60758&amp;sd=2025-08-29","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/","name":"Abbott's Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG60758&amp;sd=2025-08-29","datePublished":"2025-08-29T12:39:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG60758&amp;sd=2025-08-29","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG60758&amp;sd=2025-08-29"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbotts-navitor-tavi-system-receives-ce-mark-for-expanded-indication-to-treat-more-people-with-aortic-stenosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abbott&#8217;s Navitor\u2122 TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=880471"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880471\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=880471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=880471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=880471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}